Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severity

Article activity feed

1. Version published to 10.1016/j.xcrm.2021.100329

   Jul 1, 2021
2. 

   ScreenIT

   Mar 1, 2021

   SciScore for 10.1101/2020.10.07.20208603: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IRB: All testing and archiving of human specimens was approved by NYSDOH Institutional Review Board (IRB 20-021).
   Randomization	The data was randomly separated into training (70%) and testing (30%) subsets.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   COVID-19 Serum Samples: Studies were performed on sera from clinical specimens submitted to the Wadsworth Center, New York State Department of Health for determination of antibody reactivity to SARS-CoV-2.	SARS-CoV-2 suggested: None
   Serum samples (25 µL at 1:100 dilution) and antigen-conjugated …

   SciScore for 10.1101/2020.10.07.20208603: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IRB: All testing and archiving of human specimens was approved by NYSDOH Institutional Review Board (IRB 20-021).
   Randomization	The data was randomly separated into training (70%) and testing (30%) subsets.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   COVID-19 Serum Samples: Studies were performed on sera from clinical specimens submitted to the Wadsworth Center, New York State Department of Health for determination of antibody reactivity to SARS-CoV-2.	SARS-CoV-2 suggested: None
   Serum samples (25 µL at 1:100 dilution) and antigen-conjugated microspheres (25 µL at 5⨯104 microspheres/mL) were mixed and incubated 30 minutes at 37°C before washing and further incubation with phycoerythrin (PE)-conjugated secondary antibody.	antigen-conjugated microspheres (25 suggested: None
   The PE-conjugated antibodies were chosen to specifically recognize, as indicated, total antibodies (pan-Ig), or, individually IgM, IgA, IgG, IgG1, IgG2, IgG3, IgG4.	IgA, IgG suggested: None IgG1 suggested: None IgG2, IgG3 suggested: None IgG4 suggested: None
   For the detection of SARS-CoV-2 neutralizing antibodies, 2-fold serially diluted test serum (100μl) was mixed with 100μl of 150-200 plaque forming units (PFUs) of SARS-CoV-2 (isolate USA-WA1/2020, BEI Resources, NR-52281) and incubated for 1 h at 37°C, 5% CO2.	NR-52281 suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   The virus:serum mixture (100μl) was applied to VeroE6 cells (C1008, ATCC CRL-1586) grown to 95-100% confluency in 6 well plates.	VeroE6 suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)

   ---

   Results from OddPub: Thank you for sharing your code.

   ---

   Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

   Limitations of Study: The size of our patient cohort enabled a robust analysis of the antibody response to SARS-CoV-2 in individuals with self-reported mild, moderate, or severe disease. However, the addition of samples from the of the full spectrum of COVID-19 presentation, including asymptomatic individuals, and non-survivors would significantly strengthen our study. The convalescent time-point at which this study was conducted allowed us to capture a large cohort that was with well documented clinical criteria. However, the late time-point (day 40 post onset) of this study weakens the predictive capacity of our analysis for earlier points during infection. In future studies we would like to follow a comprehensive cohort of individuals from COVID-19 symptom onset through and beyond recovery to assess how the early immune response influences both disease severity, and durable memory.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
3. 

   Version published to 10.1101/2020.10.07.20208603v1 on medRxiv

   Oct 9, 2020